New Jersey Dermatology Group's Bet on AI to Outsmart Skin Cancer

CLARK, NJ – June 08, 2026 – In the quiet, high-stakes battle against melanoma, the deadliest form of skin cancer, Metropolitan Dermatology has made a significant move. The prominent New Jersey practice recently announced it is the first in the state to deploy Nevisense®, an FDA-approved technology that uses electrical signals and artificial intelligence to peer beneath the skin's surface, aiming to detect melanoma earlier and more accurately than the human eye alone.

The introduction of this tool at its Clark, Newton, and Vineland locations represents a calculated investment in a future where technology acts as a crucial ally for clinicians. "Early detection is critical when it comes to melanoma," said Dr. Alex Doctoroff, CEO and Medical Director at Metropolitan Dermatology, in a statement accompanying the announcement. "By incorporating Nevisense® into our practice, we are giving our patients access to one of the most advanced diagnostic tools available today, improving both accuracy and peace of mind."

While the announcement positions the practice at the vanguard, it also illuminates a broader, fiercely competitive landscape where various forms of advanced technology are vying to become the new standard in dermatological care. For patients, investors, and healthcare professionals, the real question is what this technology truly brings to the table and whether it signals a fundamental shift in how we fight skin cancer.

Beyond the Eye: The Science of Electrical Impedance

At the heart of Nevisense® is a technology called Electrical Impedance Spectroscopy (EIS). Unlike a visual check or even a dermatoscope that magnifies a mole's surface, EIS provides information about the unseen world beneath. The device sends tiny, painless electrical signals into a suspicious lesion and measures the tissue's resistance. The core principle is that cancerous cells, with their irregular shapes and chaotic structure, disrupt electrical flow differently than healthy, orderly cells.

This data is then analyzed by an AI-powered algorithm, which generates a score indicating the lesion's potential for malignancy. It’s a form of "augmented intelligence," designed not to replace a dermatologist but to arm them with objective data that transcends visual assessment. The clinical data is compelling. A pivotal study involving nearly 2,000 lesions found Nevisense® correctly identified 96% of melanomas. For context, the visual assessment accuracy of even experienced dermatologists hovers around 88%.

More importantly, the technology addresses one of dermatology's most persistent challenges: the high number of unnecessary biopsies. A retrospective analysis in a clinical setting showed that using EIS could reduce the "number needed to excise"—the number of benign moles removed to find one melanoma—from a high 17.5 down to just 7.8. For patients, this means fewer scalpels, less scarring, and a significant reduction in the anxiety-ridden wait for pathology results.

A Strategic Move in a Crowded Tech Field

Metropolitan Dermatology's claim to be the "only practice in NJ offering this innovative diagnostic tool" is a powerful marketing statement. While research confirms they are currently the exclusive provider of the Nevisense® system in the state, they are far from the only practice leveraging advanced technology in the fight against skin cancer. The investment landscape is dotted with competing solutions.

Across New Jersey, other leading dermatology centers are deploying different, but equally sophisticated, tools. Some utilize AI-powered full-body mole-mapping, where high-resolution photographs are analyzed by algorithms to detect subtle changes over time. Others offer 3D whole-body imaging, creating a digital avatar of a patient's skin to meticulously track lesions, a service also available at major cancer centers like Memorial Sloan Kettering's New Jersey facility. These technologies, much like Nevisense®, aim to enhance early detection and provide a more comprehensive view than a simple annual check-up.

Metropolitan's choice of Nevisense® is therefore a strategic bet on the power of EIS over purely image-based analysis. By investing in a tool that gathers biological data from beneath the skin, the practice is differentiating itself in a market rapidly embracing technological aids. It’s a move that positions them as innovators but also places them in direct competition with other high-tech approaches, each with its own proponents and price points.

Redefining the Patient Journey: Accuracy, Access, and Cost

For patients, the promise of a non-invasive, painless test that can prevent an unnecessary scar is undeniably attractive. The psychological benefit of receiving a clear, data-backed assessment that reduces uncertainty cannot be overstated. However, access to this cutting-edge technology comes with practical considerations, chief among them being cost.

The press release from Metropolitan Dermatology does not detail the price of a Nevisense® scan or its insurance coverage status. This is a critical piece of the puzzle for patients. Looking at comparable advanced screening tools in the region provides some context. For instance, a full-body 3D mapping service at one North Jersey clinic costs nearly $600 and is often paid out-of-pocket, though it may be eligible for Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA). Other AI-screening services are similarly positioned as cash-based options to avoid "insurance hassles."

This trend suggests that Nevisense® may initially exist in a similar space, as an optional, premium service not yet universally covered by insurance plans. While this makes the technology accessible to some, it raises questions about equity and whether the patients who could benefit most will be able to afford it. As with any new medical innovation, the path from a niche, out-of-pocket service to an insured standard of care is a long one, dependent on demonstrating not just clinical efficacy but also cost-effectiveness to insurers.

The long-term success of technologies like Nevisense® will hinge on this balance. By potentially reducing the high volume of costly biopsies and subsequent pathology, the system could make a strong economic case for broader insurance adoption. For now, patients in New Jersey have a powerful new option, but one that requires careful inquiry into the financial implications before booking an appointment.